PFNX News and Press, Pfenex Inc. From 10/25/19

Bausch Health Companies (NYSE: BHC ) initiated with Outperform rating and $35 (54% upside) price target at Cowen and Company. More news on: Bausch Health Companies Inc., Illumina, Inc., MannKind Corporation, Healthcare stocks news, Stocks on the move, , Read more ...

SAN DIEGO, Oct. 24, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX), a development and licensing biotechnology company focused on leveraging its Pf ēnex Expression Technology® to develop and improve protein therapies for unmet patient needs, announced today that it w...

Below are the five companies in the Biotechnology industry with the highest sales per share. Sales per share is a valuable metric in comparing relative value for companies in the same industry. AbbVie Inc. ranks highest with sales per share of $18.55. Emergent BioSolutions Inc. is next with s...

Thinly traded micro cap Pfenex (NYSEMKT: PFNX ) is up  2%  premarket on light volume in response to  results from a human factors study that showed the non-inferiority (no worse than) of the user interface of PF708 to Eli Lilly's (NYSE: LLY ) Forteo [teriparatide (rDNA origin...

Study results found that the FDA-approved PF708 product is noninferior to Forteo® based on a pre-specified statistical analysis of critical patient and caregiver tasks Pfenex believes the study report completes the information package required by the FDA to evaluate the FDA-appro...

New Exclusive Commercialization Agreements in South Korea, Canada, and Israel Submission of Marketing Authorization Application for PF708 in Saudi Arabia Potential approval of PF708 in the EU as early as the second half of 2020 SAN DIEGO, Oct. 11, 2019 (GLOBE NEWSWIRE) -- Pfen...

According to industry and sector data analysed by GlobalData, Merck's ( MRK ) Keytruda will reportedly become the world's top-selling drug by 2025, with estimated sales of over $22 billion. Wall Street consensus estimate pegs nearly $20 billion annual sales for Keytruda by 2023. Bristol-Myer...

October 8, 2019 Palm Beach, FL – October 8, 2019 – Medical device manufacturing remains a strong market, driven by technological developments, an aging population, and increases in chronic and lifestyle diseases – trends that expand healthcare spending. W...

Pfenex (NYSEMKT: PFNX ) +13%  as FDA OKs Pfenex Forteo biosimilar. More news on: Pfenex Inc., Mereo BioPharma Group plc, Livongo Health, Inc., Stocks on the move, Read more ...

Under its 505(b)(2) pathway, the FDA approves Pfenex's (NYSEMKT: PFNX ) PF708, a biosimilar to Eli Lilly's (NYSE: LLY ) osteoporosis med Forteo (teriparatide injection), for certain patients at high risk of fracture. More news on: Pfenex Inc., Eli Lilly and Company, Healthcare stocks new...